TALL-104Cell Culture Through Perfusion With Fixed-bed Stirred-tank Bioreactor And The Anti-tumor Study Of TALL-104

Objective: With the increasing of age of the world’s population,cancer was becoming the most important reason which caused humandeath, and there are approximately700million people who died withvarious cancers every year. The reasons that lead tovarious cancerswerevery broad, such as viruses, bacteria, physical factors, chemical factors,and genetic factors. In the normal immune systems, cancerous cellswould be found and eliminated at the early stage. However, cancerouscells could escape from immune systems with lower function, which leadto cancer. The usual treatments were radiotherapy, chemotherapy andsurgery surgical treatment. Among these, Cell therapy, as a method ofbiological treatment, was popular on1970s. However, there were varioustechnical problems and clinical side effects which restricted itsdevelopment. The study in the article was a non-MHC restrictedcytotoxic T cells with CD8+, which was found by Daniela Santoli on 1990s. This cell line could expand under100IU/mL interleukin-2, andcontinue to secrete cytotoxiccytokines for8h. In recently, TALL-104was combined with Imatinib mesylate to treatchronic myeloid leukemia(CML)in Europe for the Phase II clinical study. The cell was a potentialallogeneic therapytreatment, and the first problem was expansion invitro.Method: To investigate the TALL-104cell culture through Perfusionwith Fixed-bed Stirred-tank Bioreactor and the Anti-tumor ability ofTALL-104.cell concentration were calculated by detecting glucoseconcentration, using MTT to test the cytotoxicity assay of harvestcells.Results: The TALL-104cell expanded23times through Perfusionwith Fixed-bed Stirred-tank Bioreactor, which could be harvestedusing0.25%EDTA-trypsin to digest, and anti-tumor ability showed therewas no obviously difference between the cells harvested from dishes andbioreactor.Conclusion: TALL-104cell could be cultured through Perfusionwith Fixed-bed Stirred-tank Bioreactor.